Erythropoietin (Epo) has been used in the treatment of anemia resulting from numerous etiologies including renal disease and cancer. However, its effects are controversial and the expression pattern of the Epo receptor (Epo-R) is debated. Using in vivo lineage tracing we document that within the hematopoietic and mesenchymal lineage, expression of Epo-R is essentially restricted to erythroid lineage cells. As expected, adult mice treated with a clinically relevant dose of Epo had expanded erythropoiesis due to amplification of committed erythroid precursors. Surprisingly, we also found that Epo induced a rapid 26% loss of the trabecular bone volume and impaired B-lymphopoiesis within the bone marrow microenvironment. Despite the loss of trabecular bone, hematopoietic stem cell populations were unaffected.
Introduction
Anemia can result from benign conditions such as acute/chronic bleeding, dietary deficiency, renal disease or hemoglobinopathies and malignant diseases such as myelodysplastic syndrome (MDS) 1, 2 . In response, the body produces erythropoietin (Epo) 3 . Epo acts via its receptor (Epo-R), to stimulate and support increased erythropoiesis (reviewed in 4, 5 ). It has been widely used clinically for treating anemia due to numerous causes, including infection, inflammation, gastrointestinal diseases and cancer 2, 6 . However, the use of Epo in cancer treatment is controversial due to adverse effects on survival, which have been reported in some clinical trials [7] [8] [9] .
Within the erythroid lineage, Epo is essential for the survival, proliferation and differentiation of definitive progenitors. While erythroid colony-forming-units (CFUEs) are highly Epo-dependent, Epo is dispensable for later stages of erythroid development 10 . Lack of Epo signaling in the mouse results in reduced primitive erythropoiesis and death around E13 due to failure of definitive erythropoiesis 11, 12 .
Targeted disruption of Epo or its receptor Epo-R generates identical phenotypes, suggesting that there are no alternate physiological ligands or receptors 11 . In addition to its erythropoietic activity Epo has also been proposed to act as a tissue-protective factor in tissues such as the heart, blood vessels, and brain (reviewed in 13, 14 ).
However, the expression of Epo-R in non-erythroid tissues is contentious. Recently described antibody studies suggest that Epo-R is restricted to the erythroid lineage [15] [16] [17] [18] . This raises several questions regarding the effects of Epo in non-hematopoietic cell types.
We have treated wild-type mice with a clinically relevant dose of Epo 19 for 10 days, which as anticipated led to an erythropoietic response including elevated
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From hematocrit (Hct) and hemoglobin (Hgb) levels. Unexpectedly, Epo administration resulted in a rapid loss of trabecular bone and impaired B-cell development within the bone marrow (BM). The non-erythropoietic effects of Epo were likely indirect via the production of cytokines/soluble factors by the Epo-responsive erythroblasts, since Epo-R could not be detected on either B-cells or osteoblasts. These results demonstrate an in vivo regulatory nexus coordinating erythropoiesis, B-lymphopoiesis and skeletal homeostasis, which may be of relevance to the clinical application of Epo.
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Methods

Experimental mice
Nine-week-old male C57BL/6 mice (A.R.C., WA, Australia) were injected intraperitoneally (i.p) with either PBS control or 300U/kg of recombinant human Epo (rhEpo; Janssen Cilag, Epoitin alpha) every second day for 10 days, or twice with 40μg/kg of phenylhydrazine (PHZ; Sigma-Aldrich, NSW, Australia). All mice received i.p injections of 20mg/kg Calcein (Sigma) on day 4 and day 8. One cohort of mice received a single injection of PBS or Zoledronic acid (10μg/kg; Novartis Pharma AG, Basel, Switzerland) subcutaneously 3 days prior to starting Epo or control treatment. For the PHZ experiment, mice were bled on day 0 and day 5, in addition to day 10 when all experiments were terminated. For the Epo-R tracing experiments Epo-R-Cre knock-in mice 20 were crossed with B6.129X1-Gt(ROSA)26Sor tm1(EYFP)Cos reporter mice from the Jackson Laboratory (#006148).
BM from C57BL/6 mice was used for in vitro cultures. Primary calvarial osteoblasts for osteoclast-cultures were harvested as previously described 21 . All experiments were performed with approval of St Vincent's Health Melbourne AEC.
Cell preparations & Flow cytometry analysis
PB was analyzed on a hematological analyzer (Sysmex KX-21N, Roche Diagnostics, Australia). Bones were flushed, spleens crushed and single cell suspensions prepared.
Erythroid cells in the PB were lyzed before FACS analysis. Osteoblastic progenitor populations were obtained as previously described 22 . Antibodies against murine 
Colony assays
50,000/mL BM or 100,000/mL spleen cells were plated in methylcellulose medium containing 50ng/ml murine Stem Cell Factor (mSCF; PeproTech, Rocky Hill, NJ), 10ng/ml murine Interleukin 3 (mIL-3; PeproTech), 50ng/ml human IL-6 (hIL6; Amgen), and 3U/ml rhEpo (Jansen-Cilag). The methylcellulose medium used for colony assays contained 1% methylcellulose (Methocel MC #64630; Fluka), IMDM (Invitrogen), 20% BIT Serum replacement (Stem Cell Technologies, BC, Canada), penicillin/streptomycin (P/S; Gibco, VIC, Australia), GlutaMAX (Gibco) and
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In vitro cultures
For B-cell cultures, 20,000 OP9 cells/ml were plated in a 24-well plate 48 hours before 10,000 sorted Pre-Pro B-cells were added per well. B-cell cultures were performed in alpha-MEM (Sigma) with 20% fetal bovine serum (FBS; PAA Gold, Canada), P/S, GlutaMAX, 5x10 -5 M 2-mercaptoethanol (Sigma), 5 ng/ml Flt3L (PeproTech), and 1 ng/ml mIL-7 (R&D Systems, Minneapolis MN), with or without 3U/ml or 9U/ml of rhEpo. B-cell development was analyzed on day 5 and 10 (n=3/treatment). For the transwell experiment 100,000 sorted erythroblasts were added to a 0.4 μm pore size insert per well (Corning Inc., Corning, NY). B-cell development was analyzed on day 7 (n=3/treatment).
Kusa4b10 cells 23 were seeded at 3,000 cell/cm 2 in 12-well plates and differentiated into mature osteoblasts for 21 days in alpha-MEM media supplemented with 50 μg/ml ascorbate (Sigma) and 10mM beta glycerophosphate (Sigma), with or without 3U/ml or 6U/ml of rhEpo. Cells were washed, fixed, and mineralization activity was measured using Alizarin red staining (Sigma).
Osteoblast were seeded at 10,000 cells together with 100,000 ficoll enriched BM monocytes per well in 48-well plates and grown in alpha-MEM/10% FCS with or without erythroblasts, and with or without Epo (6U/ml), rmOSM (50ng/ml, R&D Systems) or rmRANKL (30ng/ml, PeproTech 
Bone and vessel analysis
Micro-computed tomography (μCT) analysis was performed according to standard procedures in the secondary spongiosa of the proximal tibia using Skyscan1076 (x-ray potential 50KVp, Kontich, Belgium) 24 . Tibias were wrapped in 70% EtOH soaked gauze, cling film within a cryovial and scanned at a voxel size of 9μm. Bones were reconstructed using NRecon (Skyscan) with smoothing of 1, ring artifact reduction of 6 and beam-hardening correction of 35%. The trabecular region of interest (ROI) was manually drawn 0.55mm from the bottom of the growth plate for 2mm. 3D modeling and analysis of the bones were done using CTAn (Skyscan), applying the marching cube tight model and upper and lower grey threshold values of 45 and 255.
Histomorphometry was carried out according to standard procedures using the Osteomeasure system (Osteo Metrics Inc., Decatur, GA). Tibias were fixed, 25 .
Immunohistochemistry of the vessels was performed in the secondary spongiosa on paraffin sections of tibiae. Antigen-retrieval was undertaken using 10mM EDTA pH7. 
Statistical analysis
The significance of results was analyzed using the unpaired two-tailed student T-test on the bases that highly inbred genetically identical mice have been used in all experiments, p<0.05 was considered significant. All data is presented as
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Results
In vivo expression of Epo-R in hematopoietic and mesenchymal cells.
The expression pattern of Epo-R is highly controversial due to questions raised over the specificity of antibodies previously used to detect its expression. To clarify the occurrence of Epo-R in vivo independently of antibodies, we used a lineage tracing strategy to map its expression pattern. By crossing Epo-R-Cre knock-in mice 20 , where Table 1 . For FACS plots see Figure 3a and 6a). The lack of myeloid Epo-R expression is consistent with the analysis of the expression of Epo-R transcript at a single cell level performed by Pronk et al. 26 . Analysis of mesenchymal and osteoblastic enriched populations from the bone microenvironment 22, 29 revealed that these niche cells do not express Epo-R (Figure 1f ). However, a low percentage of the endothelial-enriched fraction expressed eYFP (Figure 1f) , consistent with previously published data 15 . Thus, in vivo Epo-R expression within the BM microenvironment is essentially restricted to the erythroid population.
Administration of Epo induces increased erythropoiesis
To examine in detail the activity of Epo in light of the lineage tracing described above we injected 9-week-old male C57BL/6 mice every second day for 10 days with Epo 30, 31 . Furthermore, the number of CFU-E colonies was highly increased in spleens of Epo-treated mice as compared to control mice (Supplemental Figure 2g) . Thus, Epo induces expansion of the pre-CFU-E fraction in the BM and extra-medullary erythropoiesis in the spleen.
Epo treatment impairs B-cell development
Within the BM there were changes in cell populations that do not express Epo-R. The 
Epo induces a rapid loss of bone and increased bone turnover
We assessed bone parameters by analyzing tibiae from Epo-or PBS-treated mice Figure 3c) . In conclusion, Epo caused a rapid and specific increase in the rate of bone turnover and a net loss in trabecular bone, which was indirect due to the lack of detectable Epo-R expression on osteo-lineage cells.
Endogenous Epo elevations result in loss of trabecular bone
To determine whether the skeletal and B-cell phenotype could be recapitulated by an elevation of endogenous Epo, mice were injected with phenylhydrazine (PHZ) (Supplemental Figure 4a) . PHZ treatment induced a hemolytic anemia and an endogenous Epo response. By day 5 after the first PHZ injection both RBC and Hct levels in PB were reduced (Supplemental Figure 4b) . Plasma levels of endogenous Epo were elevated 7.5-fold and there was a 12-fold increase in reticulocytes (Supplemental Figure 4c) . PB parameters had largely recovered by day 10 (Supplemental Figure 4b-c) , while the numbers of erythroblasts and enucleated erythrocytes in the BM and spleen remained elevated (Supplemental Figure 4d- 
e).
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Strikingly, PHZ hemolysis resulted in impaired B-cell development with a reduction in the numbers of Pre-B cells consistent with that seen when treating with exogenous Epo (Figure 3d-e) . Furthermore, a similar bone phenotype to that observed after Epo administration was seen after acute hemolysis (Supplemental Figure 5,   Supplemental video3) . Collectively these studies demonstrate that elevations in Epo, whether exogenous or endogenous, negatively regulate bone homeostasis and BM Blymphopoiesis.
Epo reduces the number of vessels in the BM microenvironment
Sinusoidal blood vessels have proven to play an important part in the BM microenvironment 34 . Because endothelial cells express low levels of Epo-R ( Figure   1f ) we also investigated whether Epo-treatment affects blood vessels within the BM using immunohistochemistry for the endothelial marker vascular endothelial growth factor receptor 3 (VEGFR3) 35 . Surprisingly, Epo-treatment resulted in fewer ( Figure   5d and somewhat enlarged vessels (Figure 5e ), leading to a decrease in the total perimeter of vessels (Figure 5f ). However there was no difference in the total volume of vessels occupying the marrow space (Figure 5g) .
Hematopoietic stem cells are normal despite reduced trabecular bone
Osteo-lineage cells and endothelial cells are thought to constitute components of the HSC niche within the BM 34, 36, 37 . We therefore assessed the lineage-c-Kit+ Sca1+ 
Bone remodeling is necessary for normal Epo response
Erythroblasts express factors such as OncostatinM (OsM) in response to Epo 3,41 , which was also true in our hands (Supplemental Figure 3d) . OsM induces osteoblasts to secrete RANKL, and thereby potentiates osteoclast maturation from monocyte/macrophage precursors 42 . We hypothesized that the increased bone 43 , and then treated them with PBS or Epo as described. ZA completely blocked the Epo-induced decrease in bone (Figure 7a, Supplemental video4) .
Treatment with ZA/Epo also decreased the numbers of leukocytes per femur (Figure   7b ) with an accompanying trend towards increased spleen size as compared to Epo alone (Figure 7c) . Surprisingly, B-cells in mice treated with ZA/Epo were more severely reduced than with Epo alone (Figure 7d) , clearly demonstrating that the defect in B-cell development seen when treating with Epo was not coupled to the alterations in bone.
Interestingly, the PB erythroid response to Epo was blunted in ZA/Epo-treated mice with decreased RBC numbers (Figure 7e) , Hgb (Figure 7f) , and Hct levels (Figure 7g , not significant). ZA/Epo-treated PB was also macrocytic (Figure 7h) , which may reflect increased levels of reticulocytes. Taken together this suggests that bone remodeling is crucial for a normal Epo-induced erythropoietic response to occur.
In conclusion, our study reveals a novel role for Epo in coordinating the induction of erythropoiesis and bone remodeling within the BM (Figure 7i) . The distribution of Epo-R expression is a highly controversial topic and has profound implications for the therapeutic application of Epo 18, 44 . Recent studies have suggested that the antibodies previously used to detect Epo-R expression are nonspecific [15] [16] [17] [18] . We have utilized a functional in vivo lineage tracing strategy, which detected that Epo-R is first expressed in Pre-MegE and pre-CFU-E progenitors and that the erythroid daughters of these cells remain eYFP positive until they enucleate.
Our data present in vivo evidence, independent of antibody specificity, for the erythroid restricted nature of Epo-R expression within hematopoiesis. This is consistent with the most recent re-analysis of Epo-R expression on cell lines [15] [16] [17] [18] .
Importantly, we do not detect in vivo expression of Epo-R on HSCs, myeloid cells or B-lymphoid populations using the lineage tracing approach. This is in contrast to a recent report by Shiozawa et al. using an antibody based analysis 45 . We do detect expression of Epo-R in a small percentage of endothelial cells (~5%), consistent with previously published data 15 . In their study Sinclair et 49, 50 . To our surprise we could not detect mobilization or any differences in HSCs using both functional and phenotypic assessment, despite the reduction in trabecular bone. This suggests that trabecular bone, at least under certain circumstances, is not necessary for the maintenance of HSCs in the marrow space and that during these periods alternate niches within the BM may be utilized.
Blockade of bone resorption with zoledronic acid blunted the erythroid response to Epo. This unexpected outcome demonstrates that bone remodeling is a crucial physiological component of the Epo-induced erythropoietic expansion.
Collectively these data reveal a requirement for an increased space in the BM to be coupled to the hematopoietic expansion that occurs in response to a lineage instructive cytokine. 3D-analysis of the BM space has revealed that the erythroid compartment exists in the inter-trabecular spaces of the marrow 51, 52 . This localization may in part explain why the rapid remodeling of the trabecular bone is necessary to allow expanded erythropoiesis in the BM.
The majority of patients receiving Epo have renal disease and many suffer from renal osteodystrophy. Our results show that Epo is a potent inducer of bone remodeling and that this is necessary for normal erythropoietic response to occur. , although the mechanism for this is unknown. 
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